ARLP is a diversified natural resource company that generates operating and royalty income from coal produced by its mining complexes and royalty income from mineral interests it owns in strategic oil & gas producing regions in the United States, primarily the Permian, Anadarko and Williston basins. ARLP currently produces coal from seven mining complexes its subsidiaries operate in Illinois, Indiana, Kentucky, Maryland and West Virginia. ARLP also operates a coal loading terminal on the Ohio River at Mount Vernon, Indiana. ARLP markets its coal production to major domestic and international utilities and industrial users and is currently the second largest coal producer in the eastern United States. In addition, ARLP is positioning itself as an energy provider for the future by leveraging its core technology and operating competencies to make strategic investments in the fast growing energy and infrastructure transition.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
First quarter financial results. Alliance reported first quarter adjusted EBITDA and earnings per unit (EPU) of $159.9 million and $0.57, respectively, compared to $238.4 million and $1.21 during the prior year period. We had projected EBITDA and EPU of $143.8 million and $0.48. While total revenue of $540.5 million was just shy of our $541.1 million estimate, we underestimated coal sales and overstated transportation revenue. Consequently, transportation expense was also overstated. Total operating expenses were $446.2 million compared to our $462.3 million forecast.
Corporate outlook for 2025 and 2026. Management’s guidance for 2025 was little changed, except for increasing the range for total coal sales tonnage, increasing expense as a percentage of oil & gas royalty revenue, depreciation expense, and lowering net interest expense expectations. For 2026, management expects the average coal sales price per ton to trend lower. Due to higher-priced, multi-contracts rolling off, the average sales price per ton could be 4% to 5% below the midpoint of ARLP’s 2025 guidance. We think planned 2025 long wall moves and actions to improve productivity and cost effectiveness could help offset lower prices.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Key Points: – U.S. GDP shrank by 0.3%, driven by a historic 41.3% surge in imports as businesses rushed to front-load goods ahead of new Trump-era tariffs. – While consumer spending and business investment grew, rising inflation and policy uncertainty cloud near-term growth prospects. – Elevated inflation and softening growth raise the stakes for the Federal Reserve’s next policy moves, with potential implications for rate cuts.
The U.S. economy unexpectedly contracted in the first quarter of 2025, shrinking at a 0.3% annualized pace, according to Commerce Department data released Wednesday. The headline miss was driven largely by a record-breaking surge in imports, as companies raced to secure goods before a new wave of tariffs took effect under President Trump’s trade policy agenda.
This marked the first negative GDP print since early 2022 and diverged sharply from Wall Street forecasts, which had anticipated modest growth. The main culprit: a 41.3% quarterly spike in imports, with goods imports alone climbing over 50%. Since imports subtract from gross domestic product, this front-loading of supply chains delivered a mechanical but powerful hit to the quarter’s output.
While on paper this suggests economic weakness, some analysts argue that the downturn may be short-lived if imports stabilize in coming quarters. “It’s less a collapse in demand and more a reflection of distorted trade timing,” said one economist.
A Conflicting Mix for Markets and the Fed
Despite the GDP drop, consumer spending still advanced 1.8%, though this was down from the previous quarter’s 4% gain. Business investment saw strong momentum, up 21.9%, driven by firms increasing equipment spending — again, likely an effort to beat tariff hikes. On the downside, federal government spending fell 5.1%, continuing a recent pullback in public sector outlays.
Inflation data added another wrinkle to the economic picture. The personal consumption expenditures (PCE) price index, the Federal Reserve’s preferred inflation gauge, rose 3.6% in the quarter. Core PCE, which excludes food and energy, jumped 3.5%. These hotter-than-expected figures could make the Fed more cautious about cutting rates despite emerging signs of slower growth.
For small-cap and micro-cap investors, this mixed data environment adds complexity. On one hand, tariff-driven disruptions and rising input costs may squeeze margins for smaller firms with less pricing power. On the other, a potential pivot by the Fed toward easing — should growth remain weak — could lower borrowing costs and boost liquidity in risk assets.
Tariff Uncertainty and Market Sentiment
Markets are already reacting to the policy noise. Stock futures dipped on the GDP miss, while Treasury yields rose slightly, pricing in the inflation risk. Meanwhile, Trump’s “Liberation Day” tariff strategy — including broad-based 10% levies and sector-specific duties — remains in flux as negotiations continue. The president has promised a manufacturing revival, but business leaders warn that volatility in trade rules could delay investment and hiring.
From a small-cap perspective, volatility can be a double-edged sword. On one hand, it creates valuation dislocations and buying opportunities. On the other, it adds risk for companies with fragile supply chains or tight capital access. Investors may want to watch domestically focused firms with strong balance sheets and limited exposure to global inputs.
Looking Ahead
With the labor market softening — job openings recently fell to a near four-year low — and inflation still elevated, the Federal Reserve faces a high-stakes balancing act. All eyes now turn to Friday’s nonfarm payrolls report for a clearer picture of economic momentum heading into Q2.
Key Points – Consumer confidence fell to 86 in April, its lowest since early 2020. – Job openings declined to a four-year low, with inflation expectations hitting 7%. – Short-term economic outlook dropped sharply, signaling rising recession fears.
US consumer confidence took a sharp hit in April, falling for the fifth consecutive month and hitting its lowest level since the height of the COVID-19 pandemic. Amid growing anxieties around job security and inflation, data released Tuesday paints a sobering picture of how consumers view the economy — and their personal financial futures — under the growing shadow of President Trump’s trade escalation.
The Conference Board’s Consumer Confidence Index dropped to 86 in April from a revised 92.9 in March, falling short of economist expectations. Most striking was the steep drop in the Expectations Index, which gauges consumers’ short-term outlook for income, employment, and business conditions. It fell to 54.4 — a level not seen since 2011 and well below the recession-warning threshold of 80.
“Consumers were very much surprised by the severity of those tariffs,” said Yelena Shulyatyeva, senior U.S. economist at the Conference Board. “They actually expect tariffs to affect their finances and their jobs.”
April’s consumer survey, which overlapped with President Trump’s sweeping “Liberation Day” tariff announcement, reflects mounting public concern about how those policies will ripple through household budgets and the broader economy. Inflation expectations surged, with the average 12-month forecast rising to 7%, the highest in over two years.
Labor market sentiment, too, is souring. The share of respondents expecting fewer jobs in the next six months jumped to 32.1%, matching levels not seen since April 2009 during the Great Recession. That pessimism is echoed in the latest Job Openings and Labor Turnover Survey (JOLTS), which revealed that job openings slid to 7.19 million in March — the lowest since late 2020. While hiring held steady at 5.4 million, the ratio of openings to unemployed workers dropped, signaling reduced employer appetite for expansion.
“The hiring rate remains stuck at relatively low levels, which is usually consistent with a higher level of unemployment,” said Oxford Economics’ Nancy Vanden Houten, noting that the current pace of layoffs has artificially kept the unemployment rate in check.
Worryingly, consumer outlooks on income have also turned negative for the first time in five years. Fewer people now expect their income to grow, suggesting that inflation and employment concerns are affecting personal financial sentiment, not just macroeconomic views.
Still, perceptions of present-day conditions — such as current job availability and business activity — remain relatively stable. This disconnect between the present and future suggests a market caught between hope and unease, with near-term fears driven by rising costs and a softening labor environment.
Looking ahead, the April jobs report due Friday will offer a more detailed snapshot. Economists expect it to show a slowdown, with 133,000 jobs added and the unemployment rate holding steady at 4.2%. If confirmed, that would mark a meaningful shift from the stronger figures seen earlier this year.
For now, both consumers and economists are bracing for what may come next — from potential rate cuts to new fiscal shocks — in a climate increasingly shaped by political volatility and global economic uncertainty.
HOUSTON, April 29, 2025 /PRNewswire/ — Direct Digital Holdings, Inc. (Nasdaq: DRCT) (“Direct Digital Holdings” or the “Company”), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC (“Colossus SSP”) and Orange 142, LLC (“Orange 142”), today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Tuesday, May 6, 2025 after the U.S. stock market closes.
Management will host a conference call and webcast on the same day at 5:00 PM ET to discuss the results. The live webcast and replay can be accessed at https://ir.directdigitalholdings.com/.
About Direct Digital Holdings Direct Digital Holdings (Nasdaq: DRCT) combines cutting-edge sell-side and buy-side advertising solutions, providing data-driven digital media strategies that enhance reach and performance for brands, agencies, and publishers of all sizes. Our sell-side platform, Colossus SSP, offers curated access to premium, growth-oriented media properties throughout the digital ecosystem. On the buy-side, Orange 142 delivers customized, audience-focused digital marketing and advertising solutions that enable mid-market and enterprise companies to achieve measurable results across a range of platforms, including programmatic, search, social, CTV, and influencer marketing. With extensive expertise in high-growth sectors such as Energy, Healthcare, Travel & Tourism, and Financial Services, our teams deliver performance strategies that connect brands with their ideal audiences.
At Direct Digital Holdings, we prioritize personal relationships by humanizing technology, ensuring each client receives dedicated support and tailored digital marketing solutions regardless of company size. This empowers everyone to thrive by generating billions of monthly impressions across display, CTV, in-app, and emerging media channels through advanced targeting, comprehensive data insights, and cross-platform activation. DDH is “Digital advertising built for everyone.”
Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells
TNX-1700 is in preclinical development for gastric and colorectal cancers
CHATHAM, N.J., April 29, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in a poster presentation at the American Association for Cancer Research (AACR) 2025 Annual Meeting, held April 25-30, 2025, in Chicago, IL. A copy of the Company’s presentation is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com. The presentation titled, “TFF2-mediated CXCR4 partial agonism outperforms CXCR4 antagonism in reducing murine gastric cancer by suppressing PMN-MDSC generation,” demonstrated positive data in gastric cancer animal models. In the AACR presentation, a fusion protein of murine trefoil factor family member 2- murine serum albumin (mTFF2-MSA) was studied. Tonix is developing human TFF2-human serum albumin (hTFF2-HAS) as TNX-1700.
“The combination therapy of mTFF2-MSA with anti-PD1 treatment shows promise in reducing immunosuppression in the tumor microenvironment (TME) in animal models,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “We are excited to develop TNX-1700 (TFF2-HAS) as the lead program in our immuno-oncology pipeline, by testing potential dosing strategies, and establishing potential clinical biomarkers through preclinical models.”
Immunosuppressive neutrophils, also known as polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), are a major component in solid tumors that significantly hinder anti-tumor activity1,2. Despite being short-lived, their continuous replenishment from the bone marrow sustains their potent immunosuppression in the TME3. Stromal cells in the TME promote immunosuppression by recruiting MDSCs via secretion of CXCL12. Trefoil Factor 2 (TFF2), a secreted peptide of the trefoil factor family, has displayed activity as a partial agonist of CXCR44,5. Data presented in the poster demonstrated that TFF2-MSA selectively reduces immunosuppressive neutrophils and cancer-driven granulopoiesis. Treatment with TFF2-MSA, in combination with an anti-PD1 antibody, induced robust anti-tumoral CD8+ T cell responses, inhibiting tumor invasion. TFF2 reduction correlated with elevated PMN-MDSCs in gastric cancer patients, highlighting the potential negative correlation between TFF2 and PMN-MDSCs levels.
About Trefoil Factor Family Member 2 (TFF2)
Human TFF2 is a secreted protein, encoded by the TFF2 gene in humans, that is expressed in gastrointestinal mucosa where it functions to protect and repair mucosa. TFF2 is also expressed at low levels in splenic immune cells and is now appreciated to have intravascular roles in the spleen and in the tumor microenvironment. In gastric cancer, TFF2 is epigenetically silenced, and TFF2 is suggested to be protective against cancer development through several mechanisms. Tonix is developing TNX-1700 (rTFF2-HSA) for the treatment of gastric and colon cancers under a license from Columbia University. The inventor of the core technology at Columbia is Dr. Timothy Wang, who is an expert in the molecular mechanisms of carcinogenesis whose research has focused on the carcinogenic role of inflammation in modulating stem cell functions. Dr. Wang demonstrated that knocking out the mTFF2 gene in mice leads to faster tumor growth and that overexpression of TFF2 markedly suppresses tumor growth by curtailing the homing, differentiation, and expansion of MDSCs to allow activation of cancer-killing CD8+ T cells. He went on to show that a novel engineered form of recombinant murine TFF2 (mTFF2-CTP) had an extended half-life in vivo and was able to suppress MDSCs and tumor growth in an animal model of colorectal cancer. Later, he showed in gastric cancer models that suppressing MDSCs using chemotherapy enhances the effectiveness of anti-PD1 therapy and significantly reduces tumor growth. Dr. Wang proposed the concept of employing rTFF2 in combination with other therapies in cancer prevention and early treatment.
1Kim W, et al. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. Gastroenterology. 2021 Feb;160(3):781-796 2Veglia F, et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med. 2021 Apr 5;218(4):e20201803. 3Colligan SH, et al. Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression. J Clin Invest. 2022 Dec1;132(23):e158661. 4Dubeykovskaya Z, et al. Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines. J Biol Chem. 2009 Feb 6;284(6):3650-62. 5Dubeykovskaya Z, et al. Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer. Nat Commun. 2016 Feb 4;7:10517.
Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.
Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.
Important Safety Information
Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:
discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.
Do not use Zembrace or Tosymra if you have:
history of heart problems
narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
uncontrolled high blood pressure
hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation
severe liver problems
taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.
are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
an allergy to sumatriptan or any of the components of Zembrace or Tosymra
Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.
Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.
Zembrace and Tosymra may cause serious side effects including:
changes in color or sensation in your fingers and toes
sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever
cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet
increased blood pressure including a sudden severe increase even if you have no history of high blood pressure
medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
hives (itchy bumps); swelling of your tongue, mouth, or throat
seizures even in people who have never had seizures before
The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).
Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.
This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.
You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah from May 4-8, 2025, and Retina World Congress at the Marriott Harbor Beach Resort in Ft. Lauderdale, Florida from May 8-11, 2025.
“We look forward to sharing more about the potential of our modifier gene therapy platform and the meaningful results we are seeing in the clinic during these two important meetings for the retina community,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “Ocugen remains on track to deliver on our commitment to file three Biologics License Applications (BLAs)/Marketing Authorization Applications (MAAs) in the next three years—potentially addressing significant unmet medical need for large patient populations through our gene-agnostic approach.”
The ARVO Annual Meeting is a premiere gathering for eye and vision scientists from across the globe, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions. Retina World Congress brings together leading retina specialists from every continent to achieve a global scientific and clinical exchange in retinal health.
Ocugen’s presence in Utah kicks off with the Company Showcase at Eyecelerator, presented by Dr. Huma Qamar, Chief Medical Officer at Ocugen, and continues through presentations and thought leadership engagement at ARVO.
Eyecelerator @ Park City 2025
Session: Retina—Gene Therapy and Novel Mechanisms of Action Showcase Location: Grand Hyatt Deer Valley, Strawberry Ballroom, Park City, UT Date: Friday, May 2, 2025 Time: 2:06 p.m. MDT Presenter: Dr. Huma Qamar
ARVO
Exhibitor Education Forum Two-Year Follow-Up of a Phase 1/2 Clinical Trial for the Safety and Efficacy of OCU400 Novel Modifier Gene Therapy for Retinitis Pigmentosa Location: Exhibitor Floor, Section 1037 Date: Monday, May 5, 2025 Time: 2 p.m. MDT Presenter: Benjamin Bakall, MD, Ph.D., Assistant Clinical Professor, University of Arizona, College of Medicine–Phoenix, and Director for Clinical Research, Director for The Inherited Retinal Disease and Visual Function Clinic, Associated Retina Consultants
An Evaluation of the Safety and Efficacy of Novel Modifier Gene Therapy OCU410 for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Location: Exhibitor Floor, Section 1037 Date: Tuesday, May 6, 2025 Time: 2 p.m. MDT Presenter: Syed M. Shah, MD, FACS, Vice Chair for Research and Digital Medicine, Director of Retina Service at Gundersen Health System, La Crosse, Wisconsin
Safety and Efficacy of OCU410ST: A Phase 1/2 Trial of a Novel Modifier Gene Therapy for Stargardt Disease (GARDian) Location: Exhibitor Floor, Section 1037 Date: Wednesday, May 7, 2025 Time: 2 p.m. MDT Presenter: Neena Haider, Ph.D., Faculty Harvard Medical School and Founder, CEO, Shifa Precision
Paper Session Preliminary Safety and Efficacy of OCU410 for Treatment of Geographic Atrophy: Phase 1/2 OCU410: The Age-related Macular Degeneration (ArMaDa) Study Update Presentation Number: 3675 Session Number and Title: 358/AMD Clinical research II Location: Ballroom J Date: Tuesday, May 6, 2025 Time: 4:15 p.m. MDT Presenter: Syed M. Shah, MD, FACS, Vice Chair for Research and Digital Medicine, Director of Retina Service at Gundersen Health System, La Crosse, Wisconsin
Poster Session A0513: Safety and Efficacy of OCU410ST for the Treatment of Stargardt Disease: Phase 1/2 Study Update Location: Hall A-E Date: Thursday, May 8, 2025 Time: 2 p.m. MDT Presenter: Ramiro Maldonado, MD, Duke Center for Ophthalmic Genetics, Duke Pediatric Retina, Adult vitreo-Retinal diseases
Dr. Qamar will represent Ocugen at Retina World Congress to share the Company presentation and serve alongside notable retinal surgeons and industry peers during a panel discussion.
Retina World Congress
Retina Unplugged Inherited and Rare Retinal Diseases Session Moderators: Rishi P. Singh, MD, FASRS and Kourous A. Rezaei, MD Location: Grand Ballroom Date: Thursday, May 8, 2025 Time: 10:35 am – 11:12 a.m. EDT
Ocugen is committed to bringing game-changing therapies to treat inherited retinal diseases as well as blindness diseases affecting millions to market and working even harder to provide access to patients globally.
About Ocugen, Inc. Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Virginia City, Nevada, April 29, 2025 – Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) is pleased to announce that the Company’s Executive Chairman & CEO, Corrado De Gasperis, and COO, William McCarthy will be providing an overview of recent financial results and current business updates on Thursday, May 8, 2025, at 4:30pm ET. We invite all investors and other interested parties to register for the webinar at the link below.
There will be an allotted time following the live presentation for a Q&A session. Unaddressed questions will be reviewed by management and responded to accordingly. You may submit your question(s) beforehand in the registration form (linked above) or by email at: ir@comstockinc.com.
About Comstock Inc.
Comstock Inc. (NYSE: LODE) innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock’s innovations group is also developing and using artificial intelligence technologies for advanced materials development and mineral discovery for sustainable mining. To learn more, please visit www.comstock.inc.
Comstock Social Media Policy
Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
For investor inquiries: William McCarthy, Chief Operating Officer Tel (775) 413-6222 ir@comstockinc.com
For media inquiries: Tracy Saville, Director of Marketing Tel (775) 847-7573 media@comstockinc.com
Forward-Looking Statements
This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
4Q25 Results. Revenue totaled CAD$118,836, reflecting initial sales of TerraSante product. We were at $25,000. Net loss totaled $1.2 million, or a loss of $0.02/sh, in line with our estimate. For the full year, MustGrow reported revenue of $398,018 and a net loss of $4.9 million, or a loss of $0.09/sh, also in line with our expectations.
Capital Raise. In mid-January, MustGrow raised $2.585 million of capital through the sale of convertible debentures. Combined with the $3 million of cash at year-end, we believe the Company has sufficient liquidity until significant revenue begins, which we expect this year.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
FAT Brands (NASDAQ: FAT) is a leading global franchising company that strategically acquires, markets, and develops fast casual, quick-service, casual dining, and polished casual dining concepts around the world. The Company currently owns 17 restaurant brands: Round Table Pizza, Fatburger, Marble Slab Creamery, Johnny Rockets, Fazoli’s, Twin Peaks, Great American Cookies, Hot Dog on a Stick, Buffalo’s Cafe & Express, Hurricane Grill & Wings, Pretzelmaker, Elevation Burger, Native Grill & Wings, Yalla Mediterranean and Ponderosa and Bonanza Steakhouses, and franchises and owns over 2,300 units worldwide. For more information on FAT Brands, please visit www.fatbrands.com.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Fazoli’s Securitization. FAT Brands amended the Fazoli’s whole business securitization credit facility. The amendments extended the repayment and call dates from January 2025 to July 2026 and from July 2023 to October 2025, respectively, while also relaxing certain covenants, providing FAT greater operational flexibility. The new agreement also permits FAT to sell off the corporate-owned Fazoli locations.
France Growth. Also, during the month, FAT announced a new partnership to expand Fatburger across France, with the opening of 30 units over the next three years, with five units expected to be opened in 2026. FAT’s partner has a vast amount of experience within the restaurant space and successfully operates their own restaurant franchise in the country.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Key Points: – Astec Industries will acquire TerraSource Holdings for $245 million in cash, expanding its scale, global reach, and aftermarket parts business. – Astec posted a 6.5% increase in net sales to $329.4 million and more than quadrupled net income to $14.3 million year-over-year. – The acquisition is expected to be earnings accretive from day one, with $10 million in expected run-rate synergies and a 5.9x adjusted EBITDA multiple.
Astec Industries (NASDAQ: ASTE) reported a robust start to the year, posting solid first-quarter earnings and announcing a definitive agreement to acquire TerraSource Holdings, LLC in a $245 million cash deal. The acquisition, expected to close in early Q3 pending regulatory approvals, will significantly expand Astec’s scale, aftermarket revenue, and presence in adjacent material processing markets.
The Tennessee-based manufacturer of infrastructure and materials processing equipment posted Q1 net sales of $329.4 million, a 6.5% increase from the same period last year. Net income surged to $14.3 million, or $0.62 per diluted share, from $3.4 million, or $0.15 per share, in the prior year. Adjusted net income came in at $20.3 million, or $0.88 per share, while adjusted EBITDA jumped 86% to $35.2 million. Free cash flow was reported at $16.6 million.
“We are pleased to report another strong quarter in line with our plans to deliver consistency, profitability, and growth,” said Astec CEO Jaco van der Merwe. “The TerraSource acquisition adds scale and accretive margins, opens access to new markets, and strengthens our aftermarket parts offering—all aligned with our disciplined growth strategy.”
TerraSource, a material processing equipment manufacturer with over $150 million in annual revenue, brings a robust aftermarket business to the table. Roughly 60% of its revenues and 80% of its gross profit are derived from aftermarket parts—a key area of focus for Astec as it looks to increase recurring revenue and margin stability.
Astec said the deal, financed through cash on hand and new committed financing, is expected to be accretive to earnings immediately. With expected run-rate synergies of $10 million within two years and tax benefits of approximately $15 million, the transaction represents an adjusted EBITDA multiple of 5.9x.
From a segment standpoint, Astec’s Infrastructure Solutions division led Q1 performance with $236 million in sales, up 16.7% year-over-year, benefiting from strong demand in road building and concrete plants. The Materials Solutions division, however, saw a 12.7% decline to $93.4 million due to softer domestic equipment sales, though dealer interest remained high.
CFO Brian Harris emphasized the financial strength behind the transaction, noting that “TerraSource enhances our financial profile with expanded margins and quality of earnings. The acquisition aligns with our strategy and positions us for long-term growth.”
Despite a 28% year-over-year drop in backlog—down to $402.6 million—Astec remains confident in its ability to convert new demand as infrastructure markets evolve and financing capacity improves across contractor and dealer channels.
The TerraSource acquisition adds meaningful scale and global reach for Astec, reinforcing its position as a top-tier provider of material and infrastructure solutions. The company is expected to maintain its adjusted EBITDA guidance of $105 million to $125 million for the full year, excluding the pending deal.
With strong financials, a growing aftermarket footprint, and a major acquisition in play, Astec is positioning itself for long-term gains amid rising global infrastructure needs. Investors responded favorably in early trading, with Astec shares ticking higher following the announcement
Key Points: – Creating a gold-antimony producer with three cash-generating mines in Australia and Sweden. – Targeting ~160,000 gold-equivalent ounces in 2025, rising to ~180,000 ounces in 2026. – Strong balance sheet, index inclusion potential, and major growth projects underway.
Alkane Resources and Mandalay Resources have announced a transformative “merger of equals,” creating a new mid-tier gold and antimony producer with global ambitions. Under the agreement, Alkane will acquire all Mandalay shares through a court-approved plan of arrangement, offering 7.875 Alkane shares for each Mandalay share. The new combined company, retaining the Alkane Resources name, will boast a market capitalization near A$1 billion (C$898 million), with listings planned on both the ASX and TSX.
This merger creates an impressive platform of three operating, cash-generating mines: Tomingley in Australia (Alkane’s flagship), Costerfield in Australia (Mandalay’s high-margin gold-antimony asset), and Björkdal in Sweden (Mandalay’s established gold producer). Together, they are projected to deliver approximately 160,000 gold-equivalent ounces in 2025, growing to over 180,000 ounces in 2026.
The financial strength of the new entity is also notable, with a combined proforma cash balance of A$188 million as of March 31, 2025. This strong liquidity profile positions the combined company to aggressively pursue exploration, development, and potential future acquisitions, including advancing Alkane’s significant Boda-Kaiser copper-gold project.
Management continuity and expertise are at the forefront of the merger strategy. Alkane’s Managing Director, Nic Earner, will lead the combined company, alongside Mandalay executives such as COO Ryan Austerberry and VP of Exploration Chris Davis. This integration promises operational stability and continued success across all assets.
From a shareholder perspective, the merger is positioned as highly accretive. Mandalay shareholders will gain exposure to Alkane’s promising growth projects, particularly Tomingley’s ramp-up and Boda-Kaiser’s copper-gold potential. Alkane shareholders, meanwhile, benefit from immediate diversification into antimony — a critical mineral — and established production from Sweden.
Critically, the companies expect the transaction to unlock a valuation re-rate. The merged entity will target inclusion in major indices such as the ASX 300 and the GDXJ ETF, with the goal of attracting greater institutional investment and improving trading liquidity.
Both boards unanimously recommend the deal, and major shareholders, representing about 45% of Mandalay and 19% of Alkane’s shares, have already committed their support. Subject to shareholder votes, court approvals, and regulatory consents, the transaction is expected to close in the third quarter of 2025.
Industry observers see this merger as part of a broader consolidation trend among mid-tier mining companies, seeking greater scale, asset diversification, and global relevance. Alkane and Mandalay’s combination clearly fits this mold, building a stronger, growth-focused mining company with a robust balance sheet and production base.
As both companies move forward toward completing the transaction, the new Alkane Resources stands to emerge as a serious competitor in the mid-tier gold and critical minerals space — offering investors a compelling blend of production, growth, and financial strength.
Providers play crucial role in modernizing procurement systems for higher transparency, efficiency, resilience, ISG Provider Lens™ report says
STAMFORD, Conn.–(BUSINESS WIRE)– Enterprises are expanding procurement strategies beyond cost reduction, seeking to optimize processes and reduce time to market, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.
The 2025 ISG Provider Lens™ global Procurement Services report finds that procurement is becoming a strategic priority in mitigating risks and ensuring the continuity of supply chains. While wars, geopolitical unrest and rising tariffs have presented a seemingly unending series of disruptions affecting procurement in recent years, innovative companies are finding ways to make procurement a competitive differentiator.
“Enterprises recognize the need to make their procurement processes more efficient, transparent and resilient,” said Robert Stapleton, partner and lead, business process outsourcing for ISG. “At many companies, modern procurement services from leading providers play an important role in these efforts.”
Procurement teams are partnering with service providers to implement new technologies that enhance automation, data analytics and collaboration with suppliers, the report says. These include AI, generative AI, advanced analytics tools and robotic process automation (RPA). Dedicated procurement centers of excellence are developing customized solutions to meet specific enterprise requirements. Over the next 12-24 months, ISG expects companies to increase their use of advanced technologies to refine sourcing practices, enrich user experience and improve supply chain collaboration.
The use of AI and automation is rising alongside other technology trends that are reshaping enterprise procurement, the report says. Companies are using advanced analytics for granular visibility into spending patterns, supplier performance and market conditions. They are also embracing strategic sourcing based on benchmarks and best practices to enhance client-supplier relationships. Proactive risk assessments based on real-time data increase provider reliability in an unstable global environment. Circular economy practices, which improve sustainability by reducing waste, are also an increasingly common part of enterprise procurement strategies.
The use of procurement business process outsourcing (BPO) and managed services continues to grow as enterprises seek more flexible operations, ISG says. Strategic sourcing, spending data management and supplier risk and performance management are among the most common outsourced functions, while procurement technology management and sourcing governance are beginning to gain traction.
“Procurement has the potential to transform supply chain management,” said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. “Enterprises seek services and technology expertise to maximize the value of procurement systems, and providers are stepping up.”
The report also explores other procurement trends affecting enterprises, including the growing need for training to keep pace with technology and the increasing priority placed on cybersecurity in procurement systems.
For more insights into the procurement challenges facing enterprises, plus ISG’s advice for overcoming them, see the ISG Provider Lens™ Focal Points briefing here.
The 2025 ISG Provider Lens™ global Procurement Services report evaluates the capabilities of 28 providers across three quadrants: Procurement Operations Modernization Services, Strategic Sourcing and Category Management Services and Supplier Management and Contract Lifecycle Services.
The report names Accenture, Corcentric, Deloitte, Genpact, GEP, HCLTech, IBM, Infosys, TCS and WNS Procurement as Leaders in all three quadrants. It names Capgemini as a Leader in two quadrants and Tech Mahindra as a Leader in one quadrant.
In addition, Cognizant and Tech Mahindra are named as Rising Stars — companies with a “promising portfolio” and “high future potential” by ISG’s definition — in two quadrants each. ProcureAbility is named as a Rising Star in one quadrant.
In the area of customer experience, Genpact is named the global ISG CX Star Performer for 2025 among Procurement BPO Services providers. Genpact earned the highest customer satisfaction scores in ISG’s Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry.
The 2025 ISG Provider Lens™ global Procurement Services report is available to subscribers or for one-time purchase on this webpage.
About ISG Provider Lens™ Research
The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG’s global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG’s enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.
About ISG
ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
Source: Information Services Group, Inc.View all news
ATLANTA, April 28, 2025 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital transformation and cyber security solutions to federal agencies, will release financial results for the fiscal second quarter ended March 31, 2025 on May 7, 2025 after the market closes. DLH will then host a conference call for the investment community at 10:00 a.m. Eastern Time the following day, May 8, 2025, during which members of senior management will make a brief presentation focused on the financial results and operating trends. A question-and-answer session will follow.
Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256. Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call. A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 877-344-7529 and entering the conference ID 3751581.
About DLH DLH (NASDAQ: DLHC), a Russell 2000 company, enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by customers today, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,800 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of technology, innovation, and world-class expertise, to improve lives across the globe. For more information, visit www.DLHcorp.com.
INVESTOR RELATIONS Contact: Chris Witty Phone: 646-438-9385 Email: cwitty@darrowir.com
